CXCL10 and Hepatic fibrosis: Additionally, FIB-4 scores at the baseline and levels of IP-10 at the sixth year of the therapy were both higher in the group with prediabetes or T2DM, which indicates advanced hepatic fibrosis and increased inflammation.